|
Published by: Kalorama Information
Published: Oct. 1, 2009 - 1600 Pages SAVE $2,400!!Over 1,200 pages of cutting-edge research detailing the most important markets in today's diagnostic industry! Three in One Report Bundle! (Plus a bonus market alert.) Combined these reports would be over $8,490 (single user license). As a bundle, these reports are available for over 25% off cover price - a special price of $5,995.
Table of Contents
IN VITRO DIAGNOSTICS IN A RECESSIONARY ECONOMY
Table of Contents
CHAPTER ONE: Executive Summary
- Scope and Methodology
- Market Trends
- World Demand for Diagnostics
- Keys to Success
CHAPTER TWO: Introduction
- Background
- Marketing in a recession - what the experts say about the 4Ps
- Obama’s new deal - boom and bust
- Musings on what form a reformed U.S. system might take
- Status quo and future - impressing investors in a bear market
CHAPTER THREE: Market Trends/Demand Analysis
- Hospital financing
- The role of new deal for the insured, uninsured and underinsured
- Payer response to economic stress
- Demand for esoteric tests
- World market for IVD tests and services
- 2009 Market Estimates (N. America, EU West Europe, Japan, China, Latin America, India, EU East Europe, ROW)
- 2014 Market Forecasts (N. America, EU West Europe, Japan, China, Latin America, India, EU East Europe, ROW)
- Economic Conditions in United States of America
- Economic Conditions in Europe
- Economic Conditions in Japan
- Economic Conditions in China
CHAPTER FOUR: Market Overview/Supply Analysis
Market Analysis, revenue estimates 2007 - 2015
IVD Sectors Revenues
- Clinical Chemistry,
- Immunoassays - non isotopic Infectious Diseases
- Other Immunos
- Blood Bank Screening
- Hematology
- Microbiology (ID/AST)
- Molecular Microbiology
- Radioimmunoassays
- Coagulation
- Histology/Cytology
- Nucleic Acid Assays
- Blood Grouping/Typing
- Blood Bank Molecular
- Flow Cytometry
- POC -OTC diabetes
- POC -OTC other
- POC -Professional/Hospital
IVD Events
- New Tests and Technologies
- Abbott Diagnostics
- Adnavance Technologies
- Arbor Vita Corporation
- Arcxis Biotechnologies and Roche
- Assay Designs
- Aureon Laboratories
- Bayer Healthcare
- BD Diagnostics
- bioMérieux
- BRAHMS
- Caris Diagnostics
- CISBIO Bioassays
- Decision Biomarkers
- DexCom
- Diagnostic HYBRIDS
- Fujirebio Diagnostics
- GeneNews
- InVivoScribe Technologies
- Network Biosystems
- Acquisitions, Mergers
- Abbott Diagnostics-Ibis
- Beckman Coulter-Nephromics
- Exiqon A/S-Oncotech
- GE Healthcare-Whatman
- Others
- Collaborations
- Market Expansion Activities
- Lab Services
- Lab Information
- Google
- IBM
- Intel Corporation
- General Data Company
Technology
CHAPTER FIVE: Company Profiles
- Abbott Diagnostics
- Beckman Coulter Inc.
- Becton, Dickinson and Company (BD)
- bioMerieux Inc.
- Celera Corporation
- Cellestis Ltd
- Cepheid
- Clarient Inc. (formerly ChromaVision)
- deCode Genetics Inc.
- Genomic Health
- Gen-Probe Inc.
- Immucor, Inc.
- Inverness Medical Innovations
- Luminex Corporation
- Monogram Biosciences, Inc.
- Nanogen
- Ortho Clinical Diagnostics (OCD)
- Qiagen N.V.
- Quidel Corporation
- Roche Diagnostics
- Seegene, Inc.
- Sequenom, Inc.
- Siemens Medical Solutions Diagnostics
- Sysmex Corporation
- Vermillion/Ciphergen Biosystems Inc.
CHAPTER SIX: Conclusion
Pricing Strategy
Marketing Strategy
Supply and Demand
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1-1: Growth Rates Compared: World Regions
CHAPTER TWO: INTRODUCTION
- Table 2-1: Selected IVD Venture Investments
CHAPTER THREE: MARKET TRENDS/DEMAND ANALYSIS
- Table 3-1: Number of People Worldwide Who Get Chronic Diseases Every Year
- Table 3-2: Percent Change in Industrial Productivity, by Country or Region, December 2007 to December 2008
- Table 3-3: Worldwide In Vitro Diagnostic Reagent Sales by country, 2009-2014
- Table 3-4: Europe Unemployment Rates and % change in GDP
CHAPTER FOUR: Market Overview/Supply Analysis
- Table 4-1
Worldwide In Vitro Diagnostic Reagent Sales by Product Segment, 2009-2014 (Clinical Chemistry, Immunoassays, Blood Bank Screening, Hematology, Microbiology, Radioimmunoassays, Coagulation, Histology/Cytology, Nucleic Acid Assays, Blood Grouping/Typing, Blood Bank Molecular, Flow Cytometry, POC OTC diabetes, POC, OTC Other, POC, Professional/Hospital)
CHAPTER SIX: Conclusion
- Table 6-1: Pricing Structures That Create Value for the Customer
WORLDWIDE MARKET FOR IN VITRO DIAGNOSTICS, 6th EDITION
Chapter one: Executive Summary
- Overview
- Size and Growth of the Market
- Important Changes in the IVD Market
- IVD Growth in Developed Countries
- Privatization of Healthcare
- Newly Aggressive Foundations and Initiatives
- Positive and Negative Market Trends
- Human Genome Project Applications
- Remote Patient Monitoring
- Demand for Data
- The Informed Medical Consumer
- Price Point of New Products
- Focus On Home Care Raises Questions
- Top Suppliers and Niche Players
- Scope and Methodology
- Exchange Rates
- Scope
- Methodology
Chapter two: Introduction
- New Report Design
- Lab Medicine Disciplines and Applications
- Market Analysis of IVD Market Segments
- Age of the Giants and Smaller Colossuses
- Licenses and Distribution Agreements
- Top Suppliers and Niche Players
- Point of View
Chapter three: Overview of Global In Vitro Diagnostic Markets
- The Boomers and Aging Worldwide
- Healthcare Spending Worldwide
- World Segments of the IVD Market and IVD Market Evolution
- The United States
- Japan—Just Barely Holding Its Own
- Europe
- China
- India
- Africa
CHAPTER FOUR: TRENDS AND INNOVATIONS:
- Background
- Diabetes innovation
- Miniaturization And Chip Progress
- Non-Invasive Techniques And Alternative Samples
- Commercialization Issues : Patents and market innovation
- Direct to Consumer marketing
- Patient Management and Outcomes-Based Medicine
- Economics of New Tests and Technologies - the old don't disappear
- Post Genomics and Pharmacogenomics - reality check
- Growing Globalization of Public Health Crises - SARS, West Nile, Biowar impact
- Regulatory and Reimbursement Issues And Novel Devices
CHAPTER FIVE: Point-of-Care Tests
- Overview
- Special Topics
- POC in world market
- The pros and cons of POC testing
- Telemedicine Goes Wireless
- Market Analysis
- The Commercial Outlook for POC Tests
- Companies to Watch
chapter six: The Core Lab
- Core Lab Overview
- Overview of Chemistry Tests
- Special Topics
- Competing for Customer Loyalty
- Client Side
- Vendor Side
- Managed Service Plans
- Market Analysis
- Lab-based Chemistries
- Critical Care Chemistries
- Responses to Cost Pressures
- The Commercial Outlook for Chemistry Tests
- Companies to Watch
- Abaxis, Inc.
- Recent Revenue History
- Key Comment
- Details
- Abbott Diagnostics
- Recent Revenue History
- Key Comment
- Details
- Beckman Coulter Inc.
- Beckman Coulter Inc.
- Recent Revenue History
- Key Comment
- Details
- Instrumentation Laboratory (IL)
- Recent Revenue History
- Key Comment
- Details
- IRIS International, Inc.
- IRIS International, Inc.
- Recent Revenue History
- Key Comment
- Details
- Maxmat S.A.
- Maxmat S.A.
- Recent Revenue History
- Key Comment
- Details
- Nova Biomedical
- Recent Revenue History
- Key Comment
- Details
- Olympus America Inc.
- Recent Revenue History
- Key Comment
- Details
- OPTI Medical Systems, Inc.
- OPTI Medical Systems, Inc.
- Recent Revenue History
- Key Comment
- Details
- Ortho Clinical Diagnostics (OCD)
- Recent Revenue History
- Key Comment
- Details
- Probe Scientific
- Recent Revenue History
- Key Comment
- Details
- Radiometer A/S
- Recent Revenue History
- Key Comment
- Details
- Randox Laboratories
- Recent Revenue History
- Key Comment
- Details
- Roche Diagnostics
- Recent Revenue History
- Key Comment
- Details
- Siemens Medical Solutions Diagnostics
- Recent Revenue History
- Key Comment
- Sphere Medical Ltd.
- Recent Revenue History
- Key Comment
- Details
chapter seven: Immunoassays
- Overview of Immunoassays
- New Immunoassays
- Changes in the Immunoassay Market
- Special Topics
- Proteins: How Low Can You Go
- New Platforms
- immunoPCR
- FACTT
- NADIA
- ELISA
- Role of Immunoassays in Disease Management
- Market Analysis: Leading Suppliers and Growth Potential
- Regional Breakdown
- Abbott
- Roche
- Beckman Coulter
- Siemens/Bayer
- bioMerieux
- Seimens/Dade Behring
- Immunoassay Test Segments— Mature, Maturing and Emerging
- Thyroid Function
- Therapeutic drug tests
- IMx Sirolimus
- Tacrolimus
- Mature Immunoassays
- Anemia
- Fertility
- Tox/DAU
- Allergy
- Maturing Immunoassays
- Proteins
- Growth Immunoassays
- Tumor Markers
- Cardiac Markers
- Autoimmune
- Sepsis
- Diabetes
- Miscellaneous
- Point-of-care OTC and Professional Use
- Patient Self-tests (OTC)
- Pregnancy
- Fecal Occult Blood
- Breath Tests
- Professional POC
- Cholesterol
- Cardiac Markers
- Cancer Markers
- The Commercial Outlook for Immunoassays
- Companies to Watch
- Aesku Diagnostics
- Recent Revenue History
- Key Comment
- Details
- AspenBio Pharma, Inc.
- Recent Revenue History
- Key Comment
- Details
- Axela Biosensors, Inc.
- Recent Revenue History
- Key Comment
- Details
- Axis-Shield plc
- Recent Revenue History
- Key Comment
- Details
- BG Medicine Inc.
- Recent Revenue History
- Key Comment
- Details
- The Binding Site
- Recent Revenue History
- Key Comment
- Details
- Biocheck Inc.
- Recent Revenue History
- Key Comment
- Details
- BioCurex, Inc.
- Recent Revenue History
- Key Comment
- Details
- BioMarker Group
- Recent Revenue History
- Key Comment
- Details
- BioMedical Diagnostics SA (BMD)
- Recent Revenue History
- Key Comment
- Details
- Biosite Incorporated
- BioSystems International
- Recent Revenue History
- Key Comment
- Details
- Bio-Rad Laboratories Inc.
- Recent Revenue History
- Key Comment
- Details
- Chimera Biotec GmbH
- Recent Revenue History
- Key Comment
- Details
- China Medical Technologies, Inc.
- Concateno Plc
- Recent Revenue History
- Key Comment
- Details
- Conceivex, Inc.
- Recent Revenue History
- Key Comment
- Details
- Corgenix Medical Corporation
- Recent Revenue History
- Key Comment
- Details
- Crescent Diagnostics Ltd.
- Recent Revenue History
- Key Comment
- Details
- Critical Therapeutics, Inc.
- Recent Revenue History
- Key Comment
- Details
- Cylex Incorporated
- Recent Revenue History
- Key Comment
- Details
- CytoCore, Inc.
- Recent Revenue History
- Key Comment
- Details
- Diazyme Laboratories
- Recent Revenue History
- Key Comment
- Details
- Early Detect, Inc.
- Recent Revenue History
- Key Comment
- Details
- ESA Biosciences Inc.
- Recent Revenue History
- Key Comment
- Details
- Euroimmun AG
- Recent Revenue History
- Key Comment
- Details
- Fujirebio Diagnostics. Inc. (FDI)
- Recent Revenue History
- Key Comment
- Details
- Genosis Inc.
- Recent Revenue History
- Key Comment
- Details
- Grifols, S.A.
- Guava Technologies, Inc.
- Recent Revenue History
- Key Comment
- Details
- INOVA Diagnostics Inc.
- Recent Revenue History
- Key Comment
- Details
- LifeAssays AB
- Recent Revenue History
- Key Comment
- Details
- Matritech
- Recent Revenue History
- Key Comment
- Details
- Medical Services International Inc.
- Recent Revenue History
- Key Comment
- Details
- Meridian Bioscience, Inc.
- Recent Revenue History
- Key Comment
- Details
- Miraculins Inc.
- Recent Revenue History
- Key Comment
- Details
- Nanobac Pharmaceuticals Inc.
- Recent Revenue History
- Key Comment
- Details
- Nanogen
- Recent Revenue History
- Key Comment
- Details
- Onconome, Inc.
- Onconome, Inc.
- Recent Revenue History
- Key Comment
- Details
- Panacea Pharmaceuticals, Inc.
- Recent Revenue History
- Key Comment
- Details
- Phadia AB
- Recent Revenue History
- Key Comment
- Details
- Pria Diagnostics LLC
- Recent Revenue History
- Key Comment
- Details
- Pronostics Ltd.
- Recent Revenue History
- Key Comment
- Details
- Qualigen, Inc.
- Recent Revenue History
- Key Comment
- Details
- Quidel Corporation
- Recent Revenue History
- Key Comment
- Details
- Reagena Ltd.
- Recent Revenue History
- Key Comment
- Details
- Response Biomedical Corporation
- Recent Revenue History
- Key Comment
- Details
- Serion Immundiagnostica GmbH
- Recent Revenue History
- Key Comment
- Details
- Singulex Inc.
- Recent Revenue History
- Key Comment
- Details
- Spectral Diagnostics Inc.
- Recent Revenue History
- Key Comment
- Details
- Synova Healthcare, Inc.
- Recent Revenue History
- Key Comment
- Details
- TOSOH Corporation
- Recent Revenue History
- Key Comment
- Details
chapter eight: Molecular Assays
- Overview
- Special Topics
- The Special Case of Regulating Molecular Tests
- The promise of personalized medicine
- PCR Patent Update
- Molecular Testing Innovation: Technology and Players
- Market Analysis
- Nucleic Acid Tests
- Prenatal Chromosome Analysis
- Tissue Typing
- The Commercial Outlook for Molecular Tests
- Companies to Watch
- 23andMe, Inc.
- Recent Revenue History:
- Key comment:
- Details
- 454 Life Sciences Corporation
- 454 Life Sciences Corporation
- Recent Revenue History:
- Key Comment:
- Details
- Affymetrix
- Recent Revenue History:
- Key Comment:
- Details
- Almac Diagnostics
- Recent Revenue History:
- Key Comment:
- Details
- Althea Technologies, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Arcxis Biotechnologies
- Recent Revenue History:
- Key Comment:
- Details
- Asuragen, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- AutoGenomics, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- BioNanomatrix
- Recent Revenue History:
- Key Comment:
- Details
- Bruker BioSciences Corporation
- Recent Revenue History:
- Key Comment:
- Details
- Celera
- Recent Revenue History:
- Key Comment:
- Details
- CeMines, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Clinical Data, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- CombiMatrix Molecular Diagnostics (CMDX)
- Recent Revenue History:
- Key Comment:
- Details
- Consumer Genetics
- Recent Revenue History:
- Key Comment:
- Details
- Curidium Medica Plc
- Recent Revenue History:
- Key Comment:
- Details
- Sekisui Medical Co., Ltd
- Recent Revenue History:
- Key Comment:
- Details
- deCode Genetics Inc.
- Recent Revenue History:
- Key Comment:
- Details
- diaDexus Inc.
- Recent Revenue History:
- Key Comment:
- Details
- DiagnoCure
- Recent Revenue History
- Key Comment:
- Details
- DxS
- Recent Revenue history:
- Key Comment:
- Details
- eGene Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Eiken Chemical Co., Ltd
- Recent Revenue History:
- Key Comment:
- Details
- Epigenomics AG
- Recent Revenue History:
- Key Comment:
- Details
- EXACT Sciences Corporation
- Recent Revenue History:
- Key Comment:
- Details
- Exiqon A/S
- Recent Revenue History:
- Key Comment:
- Details
- Fluidigm Corporation
- Recent Revenue History:
- Key Comment:
- Details
- Gen-Probe Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Genomic Health
- Recent Revenue History:
- Key Comment:
- Details
- Genzyme Corporation
- Recent Revenue History:
- Key Comment:
- Details
- Greiner Bio-One International AG
- Recent Revenue History:
- Key Comment:
- Details
- Ipsogen
- Recent Revenue History:
- Key Comment:
- Details
- Laboratory Corporation of America Holdings (LabCorp)
- Recent Revenue History:
- Key Comment:
- Details
- Luminex Corporation
- Recent Revenue History:
- Key Comment:
- Details
- MacroArray Technologies, LLC
- Recent Revenue History:
- Key Comment:
- Details
- Med BioGene, Inc. (MBI)
- Recent Revenue History:
- Key Comment:
- Details
- Modern Technology Corp.
- Recent Revenue History:
- Key comment:
- Details
- Myriad Genetics, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Nanosphere, Inc.
- Recent Revenue History:
- Key Comment:
- Navigenics
- Recent revenue History:
- Key Comment:
- Details
- NeuroMark
- Recent Revenue History:
- Key Comment:
- Details
- NorDiag ASA
- Recent Revenue History:
- Key Comment:
- Details
- Novartis Vaccines and Diagnostics/Chiron
- Recent Revenue History:
- Key Comment:
- Details
- Nuvera Biosciences
- Recent Revenue History:
- Key Comment:
- Details
- Orion Genomics
- Recent Revenue History:
- Key Comment:
- Details
- Osmetech plc
- Recent Revenue History
- Key Comment:
- Details
- ParagonDx LLC
- Recent Revenue History:
- Key Comment:
- Details
- PerkinElmer, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Power3 Medical Products, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Progenika Biopharma
- Recent Revenue History:
- Key Comment:
- Details
- Provista Diagnostics
- Recent Revenue History:
- Key Comment:
- Details
- Psynomics Incorporated
- Recent Revenue History:
- Key Comment:
- Details
- Q Chip Ltd.
- Recent Revenue History:
- Key Comment:
- Details
- Qiagen N.V.
- Recent Revenue History:
- Key Comment:
- Details
- Quest Diagnostics Incorporated
- Recent Revenue History:
- Key Comment
- Details
- Rosetta Genomics Ltd.
- Recent Revenue History:
- Key Comment:
- Details
- Seegene, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- SensiGen LLC
- Recent Revenue History:
- Key Comment:
- Details
- Sequenom, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Source MDx
- Recent Revenue History:
- Key Comment:
- Details
- Tepnel Diagnostics Ltd.
- Recent Revenue History:
- Key Comment
- Details
- Third Wave Technologies Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Whatman plc
- Recent Revenue History:
- Key Comment
- Details
- Xenomics, Inc.
- Recent Revenue History:
- Key Comment:
- Details
chapter nine: Hematology
- Overview
- Decentralized Hematology Testing
- Market Analysis: Leading Suppliers
- The Commercial Outlook for Hematology Tests
- Companies to Watch
- Alifax S.p.a.
- Recent Revenue History
- Key Comment
- Details
- CellaVision AB
- Recent Revenue History
- Key Comment
- Details
- Chempaq A/S
- Recent Revenue History
- Key Comment
- Details
- Diesse Diagnostica Senese S.p.A.
- Recent Revenue History
- Key Comment
- Details
- ELITech Group
- Recent Revenue History
- Key Comment
- Details
- Horiba ABX S.A.
- Recent Revenue History
- Key Comment
- Details
- QBC Diagnostics, Inc.
- Recent Revenue History
- Key Comment
- Details
- Sysmex Corporation
- Recent Revenue History
- Key Comment
- Details
chapter TEN: Coagulation
- Overview of Coagulation and Immunohematology Tests
- Market Analysis
- Lab-Based Testing
- D-dimer
- Aspirin Insensitivity
- Genetic Markers of Hypercoagulopathies
- Factor V
- Warfarin
- Decentralized Coagulation Testing - Professional Use
- Decentralized Coagulation Testing - OTC
- Leading Suppliers
- The Commercial Market for Coagulation Tests
- Companies to Watch
- HemoSense, Inc.
- Recent Revenue History: 2007 $31.9 million (est)
- Key Comment
- Details
- International Technidyne Corp (ITC)
- Recent Revenue History
- Key Comment
- Details
- Diagnostica Stago
- Recent Revenue History
- Key Comment
- Details
- Trinity Biotech plc
- Revenues
- ZyCare, Inc.
- Recent Revenue History
- Key Comment
- Details
chapter eleven: Microbiology and Virology
- Overview
- Special Topics
- Hospital Acquired Infections (HAIs)
- MRSA
- HIV, a 25-year Phenomenon
- Rapid Tests for HIV
- Tuberculosis
- Cellestis
- MDR-TB
- Emerging Organisms and the Globalization of Infectious Diseases
- SARS
- Viral Hemorrhagic Fever
- Dengue
- MPV
- Globalization Brings New Threats
- Yaws
- Andenovirus type 14
- Non-Traditional Systems
- FISH
- Cell Counting by Flow Cytometry
- Laser Based Microbial Detection
- Market Analysis
- Supplies
- Microbial Identification and Antimicrobial Sensitivity Tests
- Blood Culture
- Rapid Tests
- Immunoassays - Lab based
- STDs
- Flu
- Immunoassays - Rapid
- Molecular Tests
- The Commercial Outlook for Microbiology / Virology Tests
- Companies to Watch
- 3M Medical Diagnostics
- Recent Revenue History
- Key Comment
- Details
- Accelr8 Technology Corporation
- Recent Revenue History
- Key Comment
- Details
- AdvanDx, Inc.
- Recent Revenue History
- Key Comment
- Details
- Becton, Dickinson and Company (BD)
- Recent Revenue History
- Key Comment
- Details
- bioMérieux Inc.
- Recent Revenue History
- Key Comment
- Details
- bioLytical Laboratories
- Recent Revenue History
- Key Comment
- Details
- Recent Revenue History
- Key Comment
- Details
- The BioPen Company
- Recent Revenue History
- Key Comment
- Details
- Calypte Biomedical Corporation
- Recent Revenue History
- Key Comment
- Details
- Cellestis Ltd
- Recent Revenue History
- Key Comment
- Details
- Cepheid
- Recent Revenue History
- Key Comment
- Details
- Chembio Diagnostics, Inc.
- Recent Revenue History
- Key Comment
- Details
- Common Sense Ltd.
- Recent Revenue History
- Key Comment
- Details
- Diagnostic HYBRIDS, Inc. (DHI)
- Recent Revenue History
- Key Comment
- Details
- Dynacon Inc.
- Recent Revenue History
- Ket Comment:
- Details
- Enigma Diagnostics Limited
- Recent Revenue History
- Key Comment
- Details
- GenPrime, Inc.
- Recent Revenue History
- Key Comment
- Details
- Hain Lifescience GmbH
- Recent Revenue History
- Key Comment
- Details
- HIVmirror LLC
- Recent Revenue History
- Key Comment
- Details
- Recent Revenue History
- Key Comment
- Details
- MedMira, Inc.
- Recent Revenue History
- Key Comment
- Details
- Microbionetics/IME, Inc.
- Recent Revenue History
- Key Comment
- Details
- Micro Imaging Technology, Inc. (MIT)
- Recent Revenue History
- Key Comment
- Details
- Microgen Bioproducts Ltd.
- Recent Revenue History
- Key Comment
- Details
- Mobidiag Oy
- Recent Revenue History
- Key Comment
- Details
- Molzym GmbH & Co. KG
- Recent Revenue History
- Key Comment
- Details
- Monogram Biosciences, Inc.
- Recent Revenue History
- Key Comment
- Details
- Myconostica, Ltd.
- Recent Revenue History
- Key Comment
- Details
- OraSure Technologies, Inc.
- Recent Revenue History
- Key Comment
- Details
- Oxoid
- Recent Revenue History
- Key Comment
- Details
- Pathway Diagnostics Corporation
- Recent Revenue History
- Key Comment
- Details
- Pocared Diagnostics Ltd
- Recent Revenue History
- Key Comment
- Details
- SIRS-Lab
- Recent Revenue History
- Key Comment
- Details
- StatSure Diagnostic Systems, Inc.
- Recent Revenue History
- Key Comment
- Details
- TREK Diagnostic Systems
- Recent Revenue History
- Key Comment
- Details
chapter twelve: Blood Banking Services
- Overview
- Donor Pools, Costs, Safety, Blood Supply
- The Safety Imperative
- Chagas
- West Nile
- Hepatitis and HIV
- Platelets
- Market Analysis
- Blood Grouping
- Immunoassays
- Nucleic Acid Testing (NAT) Continues to Grow
- The Commercial Outlook for Blood Banking
- Companies to Watch
- Cerus Corporation
- Recent Revenue History:
- Key Comment:
- Details
- Navigant Biotechnologies, LLC
- Recent Revenue History:
- Key Comment:
- Details
- Haemonetics Corporation
- Recent Revenue History:
- Key Comment:
- Details
- Immucor, Inc.
- Recent Revenue History:
- Key Comment:
- Details
- Medion Diagnostics AG
- Recent Revenue History: Private
- Key Comment:
- Details
- Pall Corporation
- Recent Revenue History:
- Key Comment:
- Details
- Sanquin Reagents
- Key Comment
- Verax Biomedica Inc.
- Recent Revenue History
- Private
- Key Comment
- Details
chapter thirteen: Histology and Cytology
- Overview
- Special Topics
- Cancer Drives Histology/Cytology Development
- The Future of the Pap Smear & HPV testing
- Market Analysis
- Histology/Cytology
- Traditional Stains
- In situ Hybridization Products: ISH, CISH and FISH
- Immunohistochemistry and in situ Hybridization
- Flow Cytometry
- The Commercial Outlook for Histology and Cytology Tests
- Companies to Watch
- Agendia B.V.
- Recent Revenue History:
- Key Comment
- Details
- Aperio Technologies, Inc.
- Recent Revenue History
- Private
- Key Comment
- Details
- Applied Imaging Corp./Genetix
- Recent Revenue History
- Key Comment
- Details
- AviaraDx (formerly Arcturus Biosciences)
- Recent Revenue History
- Key Comment
- Details
- BioImagene, Inc.
- Recent Revenue History
- Key Comment
- Details
- BIOVIEW, Inc.
- Recent Revenue History
- Key Comment
- Details
- Celerus Diagnostics
- Recent Revenue History
- Key Comment
- Details
- Clarient Inc. (formerly ChromaVision)
- Recent Revenue History
- Key Comment
- Details
- Compucyte Corporation
- Recent Revenue History
- Key Comment
- Details
- Cytyc Corporation
- Recent Revenue History
- Key Comment
- Details
- Dako A/S
- Recent Revenue History
- Key Comment
- Details
- Diamics, Inc.
- Recent Revenue History
- Key Comment
- Details
- Digene Corporation
- Recent Revenue History
- Key Comment
- Details
- eXagen Diagnostics, Inc.
- Recent Revenue History
- Key Comment
- Details
- HistoRx, Inc.
- Recent Revenue History
- Key Comment
- Details
- Ikonisys Inc.
- Recent Revenue History
- Key Comment
- Details
- Immunicon Corporation
- Recent Revenue History
- Key Comment
- Details
- InterGenetics, Inc.
- Recent Revenue History
- Key Comment
- Details
- MDS/Molecular Devices Corporation
- Recent Revenue History
- Key Comment
- Details
- MonoGen
- Recent Revenue History
- Key Comment
- Details
- mtm laboratories AG
- Recent Revenue History
- Key Comment
- Details
- Pathwork Diagnostics (formerly Predicant Biosciences)
- Recent Revenue History
- Key Comment
- Details
- Perceptronix Medical Inc.
- Recent Revenue History:
- Key Comments
- Details
- Rational Therapeutics
- Recent Revenue History
- Key Comments
- Details
- Tripath Imaging, Inc.
- Recent Revenue History:
- Key Comments
- Details
- Ventana Medical Systems. Inc.
- Recent Revenue History
- Key Comment
- Details
- Veridex, LLC
- Recent Revenue History
- Key Comment
- Details
- Vision BioSystems Ltd/Danaher Corp.
- Recent Revenue History:
- Key Comment
- Details
Table of Exhibits
CHAPTER ONE: Executive Summary
- Figure 1-1: World In Vitro Diagnostics Market 2007-2012 ($millions)
- Table 1-2: Worldwide In Vitro Diagnostic Reagent Sales by Country/Region 2007-2012
- Figure 1-2: Regional Market Share of In Vitro Diagnostics Market, 2007 (North America, EU, Japan, Latin America, Eastern Europe, India, China, ROW)
- Table 1-3: Top Tier IVD Companies, 2007 (Company, Country)
- Figure 1-3 Share of Top Tier Companies, 2007 vs. 2005
- Table 1-1: Exchange Rate Fluctuations, 2003-2007
CHAPTER TWO: Introduction
- Figure 2-1: Worldwide IVD Market Share by Segment
- Table 2-1: Worldwide In Vitro Diagnostic Sales by Product Market 2007-2012, $ million
- Table 2-2: Selected Diagnostics Industry Acquisitions, 2006-2007
- Table 2-3: Selected Diagnostics Industry Distribution Agreements 2006-2007
- Table 2-4: Selected Diagnostics Industry Collaborations and Licensing Agreements, 2006-2007
- Table 2-5: Revenues of Selected IVD Companies, 2005-2007
CHAPTER THREE: OVERVIEW OF WORLD IVD MARKETS
- Table 3-1: Number of People Who Get Chronic Diseases Every Year Worldwide by Disease
- Table 3-2: WHO Health Spending Statistics
- Figure 3-1: Health Expenditure as a Share of GDP, Developing Countries
- Figure 3-2 Health Expenditure per Capita: Private and Public
- Table 3-3: Worldwide In Vitro Diagnostics Sales by Country/Region 2007-2012
- Table 3-4: European Union IVD Sales by Country 2006
- Figure 3-3: Chinese Market for IVD Reagents 2007-2012
- Figure 3-4: Indian Market for IVD Reagents 2007-2012
CHAPTER FIVE: Point-of-Care Tests
- Table 5-1: POC Sales by Test Category, worldwide 2007-2012
- Table 5-2: World Glucose Monitoring Sales, by Company, 2005 - 2007
- Table 5-3: Selected Blood Glucose Test Devices Innovations, 2006-2007
- Table 5-4: Selected Blood Glucose Test Devices Innovations, 2006-2007
CHAPTER SIX: THE CORE LAB
- Table 6-1: Clinical Chemistry/Immunoassay Sales, 2007-2012
- Table 6-2: Chemistry/Immunochemistry Sales of Top Five Manufacturers, 2003-2005
- Table 6-3: Selected Workstation Innovations, 2006-2007
- Table 6-4: Worldwide Clinical Chemistry Sales by Test Category 2007-2012 (General Chem, Blood Gases, Urinalysis, Critical Care, POC)
- Figure 6-1: Worldwide Clinical Chemistry Sales by Test Category (General Chem, Blood Gases, Urinalysis, Critical Care, POC)
- Table 6-5: Selected Small Lab Workstations, 2006-2007 (Company, Location, Details, Status)
CHAPTER SEVEN: IMMUNOASSAYS
- Table 7-1: Selected New Immunoassay Platforms, 2007
- Table 7-2: Selected Small Footprint Immunoassay Systems
- Table 7-3: Worldwide Lab-Based Immunoassay Sales by Analyte Type 2007-2012 (ID, Tumor Markers, Cardiac Markers, Diabetes/HbA1c, Thyroid, Proteins, Autoimmune, Anemia, Therapeutic Drugs, Fertility, Allergy, Drugs of Abuse)
- Table 7-4: Revenue History of Leading Immunoassay Vendors, $ million 2005-2007
- Table 7-5: Selected Tumor Marker Innovations, 2006-2007
- Table 7-6: Selected Cardiac Marker Innovations, 2006-2007
- Table 7-7: Selected Autoimmune Immunoassay Innovations, 2006-2007
- Table 7-8: Selected Sepsis Marker Innovations, 2006-2007
- Table 7-9: Selected Immunoassay Innovations, 2006-2007
- Table 7-10: Regional Breakdown of POC Immunoassay Market
- Figure 7-1 Regional Breakdown of POC Immunoassay Market
- Figure 7-2: Growth Rate of Immunoassays (All Immunoassays, POC OTC Immunoassays and Professional POC)
- Table 7-10: POC OTC Immunoassay Test Sales by Test Category 2007-2012 (Pregnancy/Ovulation, Fecal Occult Blood, Drugs of Abuse, Cholesterol)
- Table 7-11: Selected OTC Test Devices, 2007
- Table 7-12: Professional POC Testing 2005-2010 (Pregnancy, Cardiac Markers, Cholesterol/Lipids, HbA1, Fecal occult blood, Cancer Markers, Drugs of Abuse, Other)
- Table 7-13: Selected Professional POC Tests on the Market and in Development, 2006-2007
CHAPTER EIGHT: Molecular Assays
- Table 8-1: Selected Molecular Test Innovations, 2006/07
- Table 8-2: Selected Nucleic Acid Testing Platforms, 2006-2007
- Table 8-3: Selected Molecular Test Services, 2007
- Table 8-4: Worldwide Molecular Test Sales by Type, $million 2007-2012
- Table 8-5: Molecular Test Revenues of Selected IVD Vendors, 2005-2007
- Table 8-6: Selected Molecular Sample Preparation Products
- Table 8-7: Worldwide Molecular Test Sales, 2005-2010 (Sales in millions)
- Table 8-8: Most Frequently Requested Genetic Tests
CHAPTER NINE: Hematology
- Table 9-1: Selected New Hematology Analyzer Tests 1990s - 2007
- Table 9-2: Selected New Hematology Research Projects
- Figure 9-1: Estimated Market for Manual and Automated Sed Rates 2007-2012
- Table 9-3: Selected Automated ESR Systems, 2007
- Figure 9-2: Estimated Share of Hematology Market by Setting (Central vs Decentralized) 2007
- Table 9-4: Selected POC Hematology Systems, 2007
- Figure 9-3: Estimated Distribution of Hemoglobin Testing Volume by Region (U.S., Europe, ROW)
- Table 9-5: Revenue History of the Major Hematology Vendors by Company 2001-2007
- Figure 9-4: Market Share of Hematology Vendors 2007
- Figure 9-5: World Market for Hematology 2007-2012
- Figure 9-6: Estimated Distribution of Hematology Revenues by Region (U.S., Europe, Japan, ROW) 2007
- Table 9-6: Selected Hematology Innovations (Company, Location, Segment, Details, Market Status) 2006-2007
CHAPTER TEN: Coagulation
- Table 10-1: Worldwide Coagulation Sales by Segment 2007-2012
- Figure 10-1: Regional Share of Coagulation Market, 2007
- Figure 10-2: Lab-Based Coagulation Testing 2007-2012
- Table 10-2: Selected Coagulation Automation Innovations
- Figure 10-3: Growth Rate in Coagulation Testing Segments (Genetic Markers compared to Lab-Based, POC Self Test, and POC Professional)
- Table 10-3: Selected New Warfarin Sensitivity Tests, 2006-2007 (Company, Location, Test, Status)
- Figure 10-4 Decentralized (POC) Coagulation Testing, Professional: 2007 and 2012 ($millions)
- Figure 10-5: Coagulation POC Testing by Region (US, Europe, ROW)
- Table 10-4: CLIA Waived PT Devices
- Figure 10-6: Decentralized (POC) Coagulation Testing, Over the Counter: 2007 and 2012
- Table 10-5: Top Coagulation Company Revenues 2005 - 2007
- Table 10-6: Selected Coagulation Test Innovations 2006-2007
chapter eleven: Microbiology and Virology
- Table 11-1: Percent of Staph infections Among U.S. Intensive Care Patients That Are Infected with MRSA
- Table 11-2: CLIA waved Tests for HIV Market
- Table 11-3: Selected HIV Test Innovation, 2007
- Table 11-4: PCR, FISH, Flow and Cell Imaging Systems for Bacteria / Virus Detection, 2007 and 2012 ($million)
- Table 11-5: Worldwide Microbiology/Virology Sales by Type 2007-2012
- Table 11-4: Selected Chromogenic Growth Media
- Table 11-6: Revenue of Selected ID/AST Product Companies, 2007
- Table 11-7: Selected Microbiology/Virology Innovations, 2006-2007 (Company, Location, Details, Status)
- Table 11-8: Selected Immunoassays for Sepsis (Company, Location, Details, Status)
- Table 11-9: Selected Syphilis Immunoassays, 2007
- Table 11-10: Selected Infectious Disease Immunoassay Innovations, 2006-2007
- Table 11-11: Selected POC Tests for Infectious Diseases, 2006-2007
- Figure 11-1: Molecular Tests vs. Traditional Lab-Based Immunoassays 2005-2012 ($millions)
- Table 11-12: Molecular Test Sales, Infectious Diseases by Type (HIV, Hepatits, GC/Chlamydia, Organism ID, MRSA et. al, Mycobacteria, TB, Respiratory, Others), 2007-2012 ($ Millions)
- Figure 11-2: Molecular Test Sales, Infectious Diseases by Type (HIV, Hepatits, GC/Chlamydia, Organism ID, MRSA et. al, Mycobacteria, TB, Respiratory, Others), 2007-2012
- Figure 11-3 Molecular Testing Emerging Infectious Disease vs. First Wave
- Table 11-13: Selected Infectious Disease Molecular Test Innovations, 2006-2007
CHAPTER TWELVE: Blood Banking Services
- Table 12-1: Selected Blood Treatment Systems, 2007
- Table 12-2: Worldwide Blood Bank Sales, 2007-2012 (ABO Grouping, Immunoassay Screen, NAT Screen)
- Table 12-2: Worldwide Blood Bank Sales, 2007 and 2012 ($ millions)
- Figure 12-1: ABO Grouping Revenues by Region (North America, EU, Japan, ROW)
- Table 12-3: Selected Blood Grouping Innovations, 2006-2007
- Table 12-4: Selected Blood Screen Immunoassay Innovations, 2006-2007
- Table 12-5: Selected Blood Bank Innovations, 2006-2007
chapter thirteen: Histology and Cytology
- Table 13-1: Selected IVD Cancer Markers
- Table 13-2: Selected Microscopy and Image Analysis Product Companies
- Figure 13-1: The Future of Pap Smear Testing, 2005 and 2012
- Table 13-3: Selected Advanced HPV Tests, 2006-2007
- Table 13-4: Worldwide Histology/Cytology Sales by Type 2007-2012 ($million)
- Figure 13-2: Worldwide Histology/Cytology Sales by Type 2007-2012 ($million)
- Table 13-5: Worldwide Flow Cytometry Sales 2007-2012 ($million)
- Table 13-6:Worldwide CTCs and Tissue Microarray Sales 2007-2012
- Table 13-7: Selected Vendors of Traditional Histology Stains
- Table 13-8: Revenues of the Major Automated Histology Companies $ million, 2003-2007
- Figure 13-3: Revenues of the Major Automated Histology Companies, 2003-2007 ($millions)
WHAT IS WORKING IN IVD
TABLE OF CONTENTS
EXECUTIVE SUMMARY
Scope and Methodology
Keys to Success
INTRODUCTION
Background
Crucial Keys to Successful New Product Commercialization - Six Strengths Model
Point of View
Strength Point One - STRATEGIC PLANNING
Clinical Trial and Information Management
- Qiagen/Digene
- Aspen Bio AppyScore
- AdvanDx PNA FISH test
- Epigenomics PRESEPT
- Genomic Health Oncotype DX
- Hologic
Product Development
- PGxHealth
- Evidenced Based Medicine
Pricing Challenges
- Down Economy Pricing Advice
- Five Steps to Value Pricing
- Pricing as an Impression
Distribution Strategies- Examples of IVD Distribution Arrangements
- Test Commercialization
A New look at Customer Segmentation- Finding "Buckets Within Buckets" of Customers
Conclusion
Strength Point Two - MANAGING INTELLECTUAL PROPERTY
Some IP and Patent Basics
Barriers to Patent Protection
Gene Patents
To Partner Or Not
Conclusion
Strength Point Three - MANAGING THE REGULATORY PROCESS
Overview Of Regulatory Trends
Multiplexed and Molecular Tests
Regulatory Process by Region/Country
- United States
- European Economic Union
- Japan
- China
- India
Strength Point Four - ASSURING PRODUCT REIMBURSEMENT
Reimbursement Issues and Strategies
Governments React
IVDs in Obama’s Healthcare World
Wins and Disappointments
- Genomic Health
- Biosite/Inverness Medical Innovations
- Digene/Qiagen
Conclusion
Strength Point Five - MANAGING THE PRODUCT LIFE CYCLE
PR - Tell Your Story
Scale-UP Issues
Building a Supportive Organizational Structure
Strength Point Six - MANAGING MARKET FORCES
Investors- Venture Capital Activities in IVD
Consumer Power
- Steps between Evaluation of Needs and a Purchase Decision
Scientific/Medical Community
Payer Groups
Conclusion
SWINE FLU MARKET ALERT
TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
Background
Exhibit 1: Flu Epidemics Compared to Present 1918-Today
Scope And Methodology
Point of View
Information Sources
CHAPTER TWO: 2009 SWINE INFLUENZA AND
OTHER FLU EPIDEMICS
- Influenza Overview
- Overview of Virus Types
- What’s So Special About This Latest Flu?
- Flu Therapeutics
- WHO Global Influenza Preparedness Plan
CHAPTER THREE: FLU DIAGNOSTICS
- Background
- Exhbit 2: Influenza Test Innovations, 2009
(Company, Technology, Test Details, Status)
- Immunoassays
- Rapid Testing
- Market Performance of Rapid Test
- New Entrant Possiblity
- Conclusion: Impact of Swine Flu on Rapid Testing
- Molecular Assays
- Molecular Influenza Detection Techniques
- PCR, Sequencing or Both
- Lessons and Market Impact of the H5N1 Epidemic
CHAPTER FOUR: PROGNOSIS FOR A/H1N1
- Background
- Pandemic - Where? When?
- 1976 Hsw1N1 Swine Flu Case
- Comparing Past Flu Epidemics to 2009
- International Reaction
- Swine Flu and the IVD Industry
- Origin of Flu Virus Mixes
- PCR Test Development
- Late-Breaking Research Developments
- Use of Rapid Tests in Current Epidemic
CHAPTER FIVE: COMPANIES AND PRODCUTS IMPACTED
BY SWINE FLU EPIDEMIC
- Immunoassays
- 3M Medical Diagnostics
- Becton, Dickinson and Company (BD)
- Genzyme Corporation
- Inverness Medical Innovations
- Meridian Bioscience, Inc.
- Quidel Corporation
- Remel, Inc.
- Response Biomedical Corporation
- Molecular Tests
- Arbor Vita Corporation
- CombiMatrix Molecular Diagnostics (CMDX)
- Diagnostic HYBRIDS, Inc. (DHI)
- eGene Inc.
- Eiken Chemical Co., Ltd
- Life Technologies/Applied Biosystems/ Invitrogen Corporation (ABI)
- Lab21
- Laboratory Corporation of America Holdings (LabCorp)
- Luminex Corporation
- Nanogen
- Prodesse Inc.
- Qiagen N.V.
- Seegene Inc.
- Veredus Laboratories Pte
AbstractWhat does the diagnostic market look like today, how is the continuing economic news effecting the market, and what are companies doing right now to prosper? This diagnostic industry market research bundle, with over 1,200 pages, seeks to answer these questions and provide market watchers with the most comprehensive view of the industry.
The purpose of the Kalorama Bundles is to allow companies to stretch their market research budget by providing multiple related reports, each available for sale on their own, together in one offering at a significant value. Three of Kalorama's Diagnostic Market Research Reports, in One Affordable Bundle
This Worldwide Diagnostics Market Research Bundle represents three of our most innovative and best-selling topics related to the Diagnostic Industry today. The Bundle consists of one joined PDF containing the complete edition of each of these titles. Each of these titles is intact with their own table of contents:
In Vitro Diagnostics in a Recessionary Economy: IVD Market Forecasts, Analysis and Success Strategies
This title looks at the 2009 in vitro diagnostic market and answers the question - is IVD a recession-proof market? Many experts contend that it is, but that doesn't mean there aren't danger signs that marketers will have to watch out for. Kalorama Diagnostic analyst Shara Rosen updates IVD top level category markets for 2009 and forecasts for future revenues, and provide strategic recommendations for companies operating in this economy.
The Worldwide Market for In Vitro Diagnostic Tests, 6th Edition
Complete Coverage of Immunoassays, Core Lab Tests, Molecular DX, Point of Care, Blood Banking, Hematology, Microbiology and Virology and More...
Used by the top diagnostic companies for their business planning, Shara Rosen’s report offers a great value by covering every segment of in vitro diagnostics with reliable forecasts, unprecedented company coverage and expert analysis. Published in May 2008 with a preface for the current economy written December 2008 the report covers every area of in vitro diagnostics - point of care, hematology, core lab, microbiology and virology, cytology and histology, blood banking, molecular diagnostics and more. The report details trends including intense consolidation and molecular testing that are shaping this industry. There are over 900 pages in this report.
What is Working in In Vitro Diagnostics Strategic Advice From Kalorama's Top Diagnostic Industry Analyst
Kalorama Information has been watching diagnostic markets for some time, and we have observed companies succeed and fail over time. With this report, you can benefit from that analysis as applied to the commercialization of diagnostic products. In this strategic report, analyst Shara Rosen consolidates her years of experience watching the in vitro diagnostic market and looks at what has tend to work and what does not. In the course of describing successful commercialization strategies, Rosen provides plenty of real-world examples.
AND an Added Bonus:
Kalorama's Swine Flu Market Alert, written in May of 2009, describes the mechanisms of the virus that has focused media and public health attention on several areas of the diagnostic industry. The report and forecasts possibilities for the impact of the continued H1N1 virus threat on diagnostic industry business plans.
Expand The Value of This Useful Resource With a Departmental License - Will 1 to 10 employees in the same company be using this title? Upgrade to a departmental license for just 20% more ($7,190)
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
